These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 15105519)

  • 1. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs.
    Sandercock P; Berge E; Dennis M; Forbes J; Hand P; Kwan J; Lewis S; Lindley R; Neilson A; Wardlaw J
    Stroke; 2004 Jun; 35(6):1490-7. PubMed ID: 15105519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pharmacoeconomic assessment of recombinant tissue plasminogen activator therapy for acute ischemic stroke in a tertiary hospital in China.
    Yan X; Hu HT; Liu S; Sun YH; Gao X
    Neurol Res; 2015 Apr; 37(4):352-8. PubMed ID: 25297471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke: experience from Australian stroke center.
    Tan Tanny SP; Busija L; Liew D; Teo S; Davis SM; Yan B
    Stroke; 2013 Aug; 44(8):2269-74. PubMed ID: 23780955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of intravenous thrombolysis with alteplase within a 3-hour window after acute ischemic stroke.
    Ehlers L; Andersen G; Clausen LB; Bech M; Kjølby M
    Stroke; 2007 Jan; 38(1):85-9. PubMed ID: 17122430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Utility Analysis of Mechanical Thrombectomy Using Stent Retrievers in Acute Ischemic Stroke.
    Ganesalingam J; Pizzo E; Morris S; Sunderland T; Ames D; Lobotesis K
    Stroke; 2015 Sep; 46(9):2591-8. PubMed ID: 26251241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Intra-Arterial Treatment as an Adjunct to Intravenous Tissue-Type Plasminogen Activator for Acute Ischemic Stroke.
    Leppert MH; Campbell JD; Simpson JR; Burke JF
    Stroke; 2015 Jul; 46(7):1870-6. PubMed ID: 26012639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential gains and costs from increasing access to thrombolysis for acute ischemic stroke patients in New Zealand hospitals.
    Te Ao B; Brown P; Fink J; Vivian M; Feigin V
    Int J Stroke; 2015 Aug; 10(6):903-10. PubMed ID: 24206567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Endovascular Stroke Therapy: A Patient Subgroup Analysis From a US Healthcare Perspective.
    Kunz WG; Hunink MG; Sommer WH; Beyer SE; Meinel FG; Dorn F; Wirth S; Reiser MF; Ertl-Wagner B; Thierfelder KM
    Stroke; 2016 Nov; 47(11):2797-2804. PubMed ID: 27758942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group.
    Fagan SC; Morgenstern LB; Petitta A; Ward RE; Tilley BC; Marler JR; Levine SR; Broderick JP; Kwiatkowski TG; Frankel M; Brott TG; Walker MD
    Neurology; 1998 Apr; 50(4):883-90. PubMed ID: 9566367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke in China.
    Pan Y; Chen Q; Zhao X; Liao X; Wang C; Du W; Liu G; Liu L; Wang C; Wang Y; Wang Y;
    PLoS One; 2014; 9(10):e110525. PubMed ID: 25329637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of recombinant tissue-type plasminogen activator within 3 hours of acute ischemic stroke: current evidence.
    Boudreau DM; Guzauskas GF; Chen E; Lalla D; Tayama D; Fagan SC; Veenstra DL
    Stroke; 2014 Oct; 45(10):3032-9. PubMed ID: 25190439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of thrombolytic treatment for stroke.
    Mar J; Begiristain JM; Arrazola A
    Cerebrovasc Dis; 2005; 20(3):193-200. PubMed ID: 16088115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of mechanical thrombectomy plus tissue-type plasminogen activator compared with tissue-type plasminogen activator alone for acute ischemic stroke in France.
    Kaboré N; Marnat G; Rouanet F; Barreau X; Verpillot E; Menegon P; Maachi I; Berge J; Sibon I; Bénard A
    Rev Neurol (Paris); 2019 Apr; 175(4):252-260. PubMed ID: 30642680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of tissue plasminogen activator for acute ischemic stroke: a comparative review.
    Tseng MC; Chang KC
    Acta Neurol Taiwan; 2004 Sep; 13(3):149-55. PubMed ID: 15508942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Burden of stroke in Italy: an economic model highlights savings arising from reduced disability following thrombolysis.
    Chiumente M; Gianino MM; Minniti D; Mattei TJ; Spass B; Kamal KM; Zimmerman DE; Muca A; Luda E
    Int J Stroke; 2015 Aug; 10(6):849-55. PubMed ID: 25854294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of tissue-type plasminogen activator in the 3- to 4.5-hour time window for acute ischemic stroke.
    Tung CE; Win SS; Lansberg MG
    Stroke; 2011 Aug; 42(8):2257-62. PubMed ID: 21719767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alteplase for the treatment of acute ischaemic stroke: a single technology appraisal.
    Jones ML; Holmes M
    Health Technol Assess; 2009 Sep; 13 Suppl 2():15-21. PubMed ID: 19804685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trial application of a Model of Resource Utilization, Costs, and Outcomes for Stroke (MORUCOS) to assist priority setting in stroke.
    Moodie ML; Carter R; Mihalopoulos C; Thrift AG; Chambers BR; Donnan GA; Dewey HM
    Stroke; 2004 May; 35(5):1041-6. PubMed ID: 15031457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
    Mark DB; Hlatky MA; Califf RM; Naylor CD; Lee KL; Armstrong PW; Barbash G; White H; Simoons ML; Nelson CL
    N Engl J Med; 1995 May; 332(21):1418-24. PubMed ID: 7723799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.